10 янв. 2024 г. · Repotrectinib had durable clinical activity in patients with ROS1 fusion–positive NSCLC, regardless of whether they had previously received a ...

11 янв. 2024 г. · Repotrectinib had durable clinical activity in patients with ROS1 fusion-positive NSCLC, regardless of whether they had previously received a ROS1 TKI.

This is the first FDA approval that includes patients with ROS1-positive NSCLC who have previously received a ROS1 tyrosine kinase inhibitor ( ...

16 февр. 2024 г. · Treatment with repotrectinib shrank tumors in a substantial number of people with advanced NSCLC with ROS1 fusions, results of the TRIDENT-1 ...

26 янв. 2024 г. · Patients with advanced-stage non-small-cell lung cancer (NSCLC) harbouring ROS1 fusions (~1–2% of all patients) can derive benefit from ROS1 ...

15 янв. 2024 г. · Repotrectinib showed durable activity and led to a response in a high percentage of patients with ROS1 fusion–positive non-small cell lung cancer (NSCLC).

A unique feature of this ROS1 TKI approval is the inclusion of robust evidence of efficacy in patients with ROS1-positive NSCLC who had ...

29 мая 2024 г. · Repotrectinib, a next-generation ROS1 TKI, has demonstrated durable clinical activity in the pivotal phase 1/2 TRIDENT-1 trial.

15 нояб. 2024 г. · Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and ...

11 янв. 2024 г. · Repotrectinib in ROS1 Fusion–Positive NSCLC. ROS1 fusions are oncogenic drivers that occur in up to 2% of patients with non–small-cell lung ...